Champions Biotechnology and Concordia Pharmaceuticals Establish Royalty Agreement for Novel Oncology Drug

ARLINGTON, Va.--(Business Wire)--
Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), today announced that
it has entered into a royalty agreement with Concordia Pharmaceuticals for the
use of Salirasib, Concordia`s novel compound for the treatment of cancer, in
combination with another targeted drug. Under the terms of the agreement,
Champions will use its Biomerk Tumorgraft Preclinical Platform to evaluate a
combination therapy indication for Salirasib, a RAS antagonist. This agreement
modifies an earlier preclinical services agreement between the companies and now
provides royalty rights for Champions Biotechnology for a specific combination
therapy indication for Salirasib in the event that required milestones are
achieved.

"This is a further example of our ability to leverage our preclinical technology
to create high potential for Champions Biotechnology while enhancing the value
of drugs for pharmaceutical and biotechnology companies," said Doug Burkett,
Ph.D., President of Champions Biotechnology, Inc. "Based on our predictive
Biomerk Tumorgraft platform, it is our intent to build a low attrition pipeline
of cancer drugs that we own, co-own or to which we have royalty rights. We are
very pleased to enter into this promising arrangement with Concordia
Pharmaceuticals."

For more information regarding Champions Biotechnology`s growing business and
recent news, please visit www.championsbiotechnology.com.

About Salirasib

Salirasib is a novel, orally available, targeted Ras inhibitor being developed
for treatment of a wide range of malignancies including pancreatic, lung, colon
and other cancers. Salirasib is not a farnesyltransferase inhibitor (FTI) or
Epidermal Growth Factor Receptor (EGFR) antagonist; Salirasib appears to inhibit
Ras signaling by dislodging all isoforms of Ras from galectin membrane binding
sites. Salirasib is the first targeted molecule to demonstrate an ability to
reduce total Ras protein levels (both wild-type and mutated) in primary human
tumors.

Clinical studies have been and are being performed at recognized Centers of
Excellence, including, M.D. Anderson (safety, pharmacokinetic and food effect
studies in both solid tumor and hematologic malignancies), Johns Hopkins
University (a Phase I/II study dosing Salirasib + Gemcitabine for the treatment
of newly diagnosed pancreatic cancer patients) and Memorial Sloan-Kettering (a
Phase II trial treating both treatment naïve and previously treated lung cancer
patients with Salirasib mono-therapy).

About Champions Biotechnology, Inc.

Champions Biotechnology, Inc. is engaged in the development of advanced
preclinical platforms and predictive tumor specific data to enhance and
accelerate the value of oncology drugs. The Company`s Preclinical Platform is a
novel approach based upon the implantation of primary human tumors in immune
deficient mice followed by propagation of the resulting engraftments (Biomerk
Tumorgrafts) in a manner that preserves the biological characteristics of the
original human tumor. Early studies suggest that these Tumorgrafts closely
reflect human cancer biology and their response to drugs is predictive of
clinical outcomes in cancer patients.

Champions Biotechnology leverages its preclinical platform to evaluate drug
candidates and to develop a portfolio of novel therapeutic candidates through
pre-clinical trials. As drugs progress through this early stage of development,
the Company plans to sell, partner or license them to pharmaceutical and/or
biotechnology companies, as appropriate. The Company also offers its predictive
preclinical platform and tumor specific data to physicians for personalized
patient care and to Companies for evaluation of oncology drugs in models that
integrate prognostic testing with biomarker discovery.

This press release contains "forward-looking statements" (within the meaning of
the Private Securities Litigation Act of 1995) that inherently involve risk and
uncertainties. Champions Biotechnology generally uses words such as "believe,"
"may," "could," "will," "intend," "expect," "anticipate," "plan," and similar
expressions to identify forward-looking statements. One should not place undue
reliance on these forward-looking statements. The Company's actual results could
differ materially from those anticipated in the forward-looking statements for
many unforeseen factors. See Champions Biotechnology's Form 10-KSB for the
fiscal year ended April 30, 2008 for a discussion of such risks, uncertainties
and other factors. Although the Company believes the expectations reflected in
the forward-looking statements are reasonable, they relate only to events as of
the date on which the statements are made, and Champions Biotechnology's future
results, levels of activity, performance or achievements, including but not
limited to the achievement of milestones as required to realize the royalties
referenced above, may not meet these expectations. The Company does not intend
to update any of the forward-looking statements after the date of this press
release to conform these statements to actual results or to changes in Champions
Biotechnology's expectations, except as required by law.

CHAMPIONS BIOTECHNOLOGY, INC. WEB SITE: www.championsbiotechnology.com

The Investor Relations Group, Inc.
James Carbonara, 212-825-3210
or
Public Relations:
Susan Morgenbesser/Janet Vasquez, 212-825-3210

Copyright Business Wire 2009